Oncomine

Test Description

The UPMC Oncomine assay is a targeted next generation sequencing assay that allows for simultaneous detection of genomic variants within 161 cancer driver genes and calculation of sample Tumor Mutation Burden (TMB). UPMC Oncomine assay assists in diagnosis, prognostication and treatment of adult and pediatric solid tumors.

Oncomine Advantage

Test Details

Genes Assayed by Oncomine

Background

The UPMC Oncomine assay is a targeted comprehensive NGS panel designed to detect multiple alterations across a wide spectrum of tumor types. These alterations include Single Nucleotide Variants (SNVs), Insertions/Deletions (indels), Copy Number (CN) alterations, and Gene Fusions covering 161 of the most relevant cancer driver genes.

Specimen Requirements

Paraffin Embedded Tissue Sections

Frozen Tissue

Turnaround Time

10-14 Business days

Billing Information

For insurance or institutional prices, please call.